Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1.   Pharmacodynamic properties
Pharmacotherapeutic group: Viral vaccine, ATC Code: J07BC02 
AVAXIM 160 U confers immunity against hepatitis A virus by inducing antibody titres greater than those obtained after passive immunisation with immunoglobulin. Antibody appears shortly after the first injection and 14 days after vaccination more than 90% of immunocompetent subjects are seroprotected (titre above 20 mIU/millilitre).
One month after the first injection, almost 100% of subjects have antibody titres above 20mIU/millilitre. Serological data show continuing protection against hepatitis A for up to 36 months in subjects who responded to the first dose. In a study of 103 healthy adults who were followed serologically for three years after the first injection of AVAXIM, 99% still had at least 20 mIU/ml anti-HAV antibody at month 36.

The long-term persistence of protective antibody levels to hepatitis A virus after a second dose (booster) of AVAXIM 160 U has not been fully evaluated.
Nevertheless, available data (antibody titres obtained two years after the second dose) suggest that anti-HAV antibodies persist beyond 10 years after the second dose in healthy individuals.

Pharmacokinetic Properties

5.2.   Pharmacokinetic properties

Not applicable.